Clinical trial · Observational
Membrane Target Detection for Leukemia Treatment
Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Study sample collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- DPP4 inhibitors measured in blood samples will be correlated with patient survival data.
- timeFrame
- 5 years
- description
- DPP4 inhibitors measured in blood samples will be used in vitro and in vivo a pre-clinical model.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All hematological malignancy patients. * Must be 18 years old. Exclusion Criteria: * Participants with impaired decision-making capacities; * Pregnant women or fetuses; * Children (under 18 in Missouri, also dependent on State law); * Non-viable neonates or neonates of uncertain viability (neonates=newborns); * Non-English-speaking subjects; * Prisoners.
References
Publications (0)
Data not yet available